US top court denies Teva stay in Copaxone patent fight

By REUTERS
April 18, 2014 23:11

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

WASHINGTON - US Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd that would have prevented a lower court ruling from going into effect while the court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

The decision could help pave the way for generic competitors to go on the market as soon as next month.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Breaking news
May 26, 2019
Unauthorized, first report: shooting attack in the West Bank

By JERUSALEM POST STAFF